Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Cost Cutting on the Way
View:
Post by SPCEO1 on Dec 03, 2022 4:16pm

Cost Cutting on the Way

THTX now needs to cut costs and do so quickly. How they do that, how quickly they do that and, most importantly, how they commuicate that to investors, will likely play a big role in how big of a bounce the stock has. 

Let's say THTX achieved $80 million in sales in fiscal 2022 just completed. If the reenrgized sales force keeps the momentum going, maybe sales grow in the 15-18% range in 2023 to $92 to $95 million. That would be a really nice outcome except for the bloated cost situation they now face. Costs in the recently reported third quarter annualize to $120 million and operating cash flow was likely negative $14-$15 million in fiscal 2022. So, they need to find that much in savings ASAP to get to cash flow breakeven at a minimum. To get to breakeven on an earnings basis they need to cut costs by 20-25%.

It is a tall order and it is an ugly turn of events for so many employees at TH. But it has to be done. 

If the revised approach to cancer yields better results, then can put back in place what they have to dismantle now as they will be able to raise money via a better priced equity offering.

Also, we better hope there is no new covid lockdowns this winter that would negatively impact sales as that would threaten the $75 million in trailing 12 month sales criteria for the second tranche of the loan meant to repay most of the remaining convertible still outstanding.  

It would also be nice to get sales up to at least the $90 million level by the end of 2023 so the third tranche can be taken down which extends the interest only portion of the loan from 2024 to 2025 and the term of the loan to 6 years from 5. They also need to get an approval for the FB by the end of 2023 to qualify for the third tranche before the incentives on the interest only and term length expire.

But first, take a hatchet to costs.
Comment by SABBOBCAT on Dec 03, 2022 5:00pm
I think I did the same look through the financials last night. Your conclusion is definitely the risk averse one. Hunker down, lick your wounds and live to fight another day. This is the only option if there isn't a compelling opportunity in the 12 month time horizon. However judging by the pivot in messaging from management and the Nash forward report from the Cantor analyst, this is what I ...more  
Comment by palinc2000 on Dec 03, 2022 5:45pm
Sabbocat I agree with what the path forward will/should be but not sure a buyout would be in order .... 
Comment by SABBOBCAT on Dec 03, 2022 5:49pm
Oh I 100% agree, but it would be nice. I just feel there would be move value in the right hands. 
Comment by palinc2000 on Dec 03, 2022 6:20pm
For sure THTX is a cash strapped company which makes execution a bigger challenge but necessity is the mother of invention....!!! A butout would be a faux fuyanr
Comment by PWIB123 on Dec 03, 2022 5:07pm
Is it possible they have a protocol amendment within days or weeks and continue as they have been, rather than slash and burn and rebuild?  If it's month's out, then yes, by all means, slash and burn.
Comment by SPCEO1 on Dec 03, 2022 9:02pm
The analysts say the company is planning to restart the trial in the first quarter. First, TH has to decide what they actually want to do in the new protocol,then the FDA has 30-60 days to decide if they are willing to endorse it. But  like most things in the drug research space, it is not unusual for it to take longer than planned.  If they get started by the end of the first quarter ...more  
Comment by Lee430 on Dec 03, 2022 9:56pm
Disillusioned is the single word I settled on, I am quickly running out of time after all these years and very much feeling like the bug & not the windshield at this point, going to try to figure out a sensible exit plan while hoping for a buyout offer....so much for my plans donating to the truly needy, thanks PL hope your living well on that $2M salary. 
Comment by SABBOBCAT on Dec 03, 2022 10:11pm
I fell that, while this is a viable path forward, it is not the optimal one. In your scenario, the company survives, but has no opportunity to deliver value to shareholders without raising significantly more capital. This leave us in a position where we have two potentially valuable yet risky we cannot realize value for. Any new investor will look at it and say, I want to be compensated for that ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities